{
  "abstract": "This study aimed to investigate the clinical efficacy and safety of dabrafenib plus trametinib for BRAFV600E-mutated advanced thyroid carcinoma in a Japanese real-world setting. We analyzed 37 BRAFV600E-mutated advanced thyroid carcinoma patients treated with dabrafenib plus trametinib between November 2023 and July 2025. Thirty-one patients (84%) had papillary thyroid carcinoma (PTC) histology, one (3%) had poorly differentiated thyroid carcinoma (PDTC) histology, and 5 (13%) had anaplastic thyroid carcinoma (ATC) histology. Among 31 PTC patients, dabrafenib plus trametinib was initiated as first-line treatment in 16 patients. The most common previous systemic therapy was lenvatinib (n = 16, 43%). The most common sites of target lesion were the lung (n = 23, 62%) and lymph node (n = 23, 62%). The median sum of the diameters of the target lesion was 40 mm (range, 8-166 mm). The objective response and disease control rates were 29% and 74% in patients with PTC, and 50% and 83% in patients with non-PTC (PDTC and ATC), respectively. The 12-month progression-free survival rates in patients with PTC and non-PTC (PDTC and ATC) were 73.2% (95% confidence interval [CI], 48.7-87.4%) and 60.0% (95% CI, 12.6-88.2%) (hazard ratio, 2.769; 95% CI, 0.691-11.1; p = 0.134), respectively. Dabrafenib plus trametinib treatment showed a response rate similar to that observed in clinical trials for BRAFV600E-mutated advanced thyroid carcinoma in this real-world study. However, long-term follow-up is required to determine the efficacy of dabrafenib plus trametinib treatment.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "Haruhiko Yamazaki"
    },
    {
      "name": "Nobuyasu Suganuma"
    },
    {
      "name": "Mei Kadoya"
    },
    {
      "name": "Katsuhiko Masudo"
    },
    {
      "name": "Ai Matsui"
    },
    {
      "name": "Aya Saito"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/92zsf35x1b83n.bib",
  "cited_by": 0,
  "doi": "10.1507/endocrj.ej25-0629",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ25-0629/_article",
  "id": "92zsf35x1b83n",
  "issns": [
    "1348-4540",
    "0918-8959"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ25-0629/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/endocrinology-metabolism"
    ],
    [
      "openalex",
      "2712|Thyroid Cancer Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7160980272",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/92zsf35x1b83n.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "10.1507/endocrj.ej25-0629",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ25-0629/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Thyroid Cancer Diagnosis and Treatment",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients",
  "title_text": "Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:20Z",
  "url": "https://research.draconitic.com/paper/92zsf35x1b83n",
  "venue": "Endocrine Journal",
  "versions": []
}